+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Acute Lymphoblastic Leukemia Market 2019 - 2025

  • ID: 4841490
  • Report
  • July 2019
  • Region: Global
  • Orion Market Research Private Limited
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie, Inc.
  • Blubird Bio, Inc.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Juno Therapeutics, Inc.
  • NexImmune Inc.
  • MORE
Acute Lymphoblastic Leukemia Market Size, Share & Trends Analysis Report by Cell Type (B-Cell and T-Cell Leukemia), by Treatment (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Stem Cell Transplantation), by End-User (Hospitals and Clinics, and Research Institutes) and Forecast, 2019-2025.

Acute lymphoblastic leukemia is a kind of blood or bone marrow cancer, commonly found in infants. The symptoms of acute lymphoblastic leukemia include pale skin, bleeding gums, fatigue, fever, and bone pain. Acute lymphoblastic leukemia can be treated by chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The global acute lymphoblastic leukemia market is expected to have a significant growth during the forecast period owing to increasing incidences of acute lymphoblastic leukemia and the number of bone marrow biopsies, globally.

The global acute lymphoblastic leukemia market is segmented on the basis of cell type, treatment, and end-user. On the basis of cell type, the market is bifurcated into B-cell type and T-cell type. Among these, B-cell type is the most common type of acute lymphoblastic leukemia, due to which the market players are working on the R&D of the drugs and therapies for the treatment of B-cell type lymphoblastic leukemia. Further, on the basis of end-user, the market is divided into hospitals and clinics, and research institutes. Among these, acute lymphoblastic leukemia market for hospitals and clinics is expected to hold significant share in the market. Increasing healthcare infrastructure is one of the major factors contributing to the growth of this segment.

Moreover, the study of the global acute lymphoblastic leukemia market report covers the analysis of four major regions that include North America (US, Canada), Europe (Germany, UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (China, Japan, India, and Rest of asia-Pacific), and Rest of the World (RoW). Asia-Pacific is expected to exhibit considerable growth during the forecast period. Further, the market players covered in the report include Pfizer, Inc., Spectrum Pharmaceuticals Inc., Novartis AG, Hoffmann La Roche Ltd., Celgene Corp., Thermo Fisher Scientific, Inc., Eli Lilly & Co., Lonza Group Ltd., and many others.

Research Methodology

The market study of the acute lymphoblastic leukemia market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Authentic Public Databases such as the National Institute of Health, the American Cancer Society, World Cancer Research Fund and others
  • Whitepapers, research-papers and news blogs
  • Company websites and their product catalog
The report is intended for research organizations, biotechnology and pharmaceutical companies, investment companies, potential entrants, venture capitalists, academic and research institutes, and government organizations for overall market analysis and competitive analysis. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:
1. Global Acute lymphoblastic leukemia Market Research and Analysis by CellType.

2. Global Acute lymphoblastic leukemia Market Research and Analysis by Treatment.

3. Global Acute lymphoblastic leukemia Market Research and Analysis by End-user.

The Report Covers:
  • Comprehensive research methodology of the acute lymphoblastic leukemia market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global acute lymphoblastic leukemia market.
  • Insights about market determinants which are stimulating the global acute lymphoblastic leukemia market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie, Inc.
  • Blubird Bio, Inc.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Juno Therapeutics, Inc.
  • NexImmune Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules &Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Pfizer, Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Spectrum Pharmaceuticals Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Novartis AG
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Hoffmann-La Roche Ltd.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Celgene Corp.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Global Acute Lymphoblastic Leukemia Market by Cell Type
5.1.1. B-Cell
5.1.2. T-Cell
5.2. Global Acute Lymphoblastic Leukemia Market by Treatment
5.2.1. Chemotherapy
5.2.2. Radiation Therapy
5.2.3. Targeted Therapy
5.2.4. Immunotherapy
5.2.5. Stem Cell Transplantation
5.3. Global Acute Lymphoblastic Leukemia Market by End-User
5.3.1. Hospitals and Clinics
5.3.2. Research Institutes

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. AbbVie, Inc.
7.2. Adaptive Biotechnologies Corp.
7.3. Amgen, Inc.
7.4. AstraZeneca PLC
7.5. Atara Biotherapeutics, Inc.
7.6. Athenex, Inc.
7.7. Baxter International, Inc.
7.8. Blubird Bio, Inc.
7.9. Bristol-Myers Squibb Co.
7.10. Cabaletta Bio, Inc.
7.11. CARsgen Therapeutics Co. Ltd.
7.12. Celgene Corp.
7.13. Daiichi Sankyo Co. Ltd.
7.14. Deciphera Pharmaceuticals LLC
7.15. Eisai Co Ltd.
7.16. Eli Lilly and Co
7.17. Erytech Pharma, SA
7.18. F. Hoffmann-La Roche Ltd.
7.19. Formula Pharmaceuticals, Inc.
7.20. Gamida Cell Ltd.
7.21. Genmab A/S
7.22. ImmunoGen Inc.
7.23. Juno Therapeutics, Inc.
7.24. Kite Pharma, Inc.
7.25. Lonza Group Ltd.
7.26. Medigene AG
7.27. NexImmune Inc.
7.28. Nimbus Therapeutics Inc.
7.29. Nohla Therapeutics, Inc.
7.30. Protheragen, Inc.
7.31. Spectrum Pharmaceuticals, Inc.
7.32. Takeda Pharmaceutical Co. Ltd.
7.33. Thermo Fisher Scientific, Inc.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie, Inc.
  • Adaptive Biotechnologies Corp.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Athenex, Inc.
  • Baxter International, Inc.
  • Blubird Bio, Inc.
  • Bristol-Myers Squibb Co.
  • Cabaletta Bio, Inc.
  • CARsgen Therapeutics Co. Ltd.
  • Celgene Corp.
  • Daiichi Sankyo Co. Ltd.
  • Deciphera Pharmaceuticals LLC
  • Eisai Co Ltd.
  • Eli Lilly and Co
  • Erytech Pharma, SA
  • F. Hoffmann-La Roche Ltd.
  • Formula Pharmaceuticals, Inc.
  • Gamida Cell Ltd.
  • Genmab A/S
  • ImmunoGen Inc.
  • Juno Therapeutics, Inc.
  • Kite Pharma, Inc.
  • Lonza Group Ltd.
  • Medigene AG
  • NexImmune Inc.
  • Nimbus Therapeutics Inc.
  • Nohla Therapeutics, Inc.
  • Protheragen, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Thermo Fisher Scientific, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll